NeuroSense Therapeutics reported an initial statement of beneficial ownership by director Mark Leuchtenberger. Mark Leuchtenberger reported direct beneficial ownership of 128,000 ordinary shares. He also reported direct beneficial ownership of 75,000 ordinary shares. He also reported direct beneficial ownership of 122,951 ordinary shares. Mark Leuchtenberger reported fully vested options to purchase 192,000 ordinary shares at a conversion or exercise price of USD 4.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-030598), on March 18, 2026, and is solely responsible for the information contained therein.
